Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines – Part 2
Manufacturing under GMP with no established playbook isn’t for the faint-hearted—especially when your therapeutic platform is first-in-class and the regulatory template hasn’t been written yet.
Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines – Part 1
What if the best way to unlock durable, broad-spectrum immunity is to rethink the very vessels delivering our vaccines?
From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic – Part 2
Translating science into real-world impact isn’t just about groundbreaking ideas—it’s a marathon of mindset, collaboration, and clarity.
From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic – Part 1
What if healing large tissue gaps was less about replacing what’s lost, and more about empowering the body to mend itself?
Engineering iPSC Neurons for Parkinson’s: From 3% Survival to Durable Graft – Part 2
What does it actually take to turn a cell therapy idea into a viable therapeutic—especially when the hurdles are higher than ever and every experiment carries real consequences for your runway?
Engineering iPSC Neurons for Parkinson’s: From 3% Survival to Durable Graft – Part 1
When it comes to neurodegenerative disease, few diagnoses evoke as much dread as Parkinson’s.
From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture – Part 2
How much of your research lives and dies on the bench—not because the idea isn’t sound, but because building reproducible, scalable biomaterials remains an unsolved puzzle?
From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture – Part 1
What if the real obstacle in 3D cell culture and tissue engineering isn’t the cells, but the very ground they grow on?
How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles – Part 2
The world of oncology constantly searches for breakthroughs, but few cancers present such stubborn challenges as glioblastoma (GBM).
How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles – Part 1
What if the answer to solid tumor therapy isn’t about making immune cells smarter—but about rethinking what a therapeutic cell can do?